A long-lasting oral preformulation of the angiotensin II AT1 receptor antagonist losartan

References

• Chakraborty S, Dhakshinamurthy GS, Misra SK. Tailoring of physicochemical properties of nanocarriers for effective anti-cancer applications. J Biomed Mater Res. 2017;105:2906–2928.
   Web of Science ®Google Scholar
• Larranaga A, Lomora M, Sarasua JR, et al. Polymer capsules as micro-/nanoreactors for therapeutic applications: current strategies to control membrane permeability. Prog Mater Sci. 2017;90:325–357.
   Web of Science ®Google Scholar
• Liversidge GG, Cundy KC. Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs.1. Absolute oral bioavailability of nanocrystalline Danazol in Beagle dogs. Int J Pharm. 1995;125:91–97.
   Web of Science ®Google Scholar
• Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev. 1999;36:101–123.
   PubMed Web of Science ®Google Scholar
• Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;224:19–38.
   PubMed Web of Science ®Google Scholar
• Liu WH, Teng LR, Yu KT, et al. Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism. Eur J Pharm Sci. 2017;96:530–541.
   PubMed Web of Science ®Google Scholar
• Gontijo SML, Guimaraes PPG, Viana CTR, et al. Erlotinib/hydroxypropyl-beta-cyclodextrin inclusion complex: characterization and in vitro and in vivo evaluation. J Incl Phenom Macrocycl Chem. 2015;83:267–279.
   Web of Science ®Google Scholar
• Stella VJ, Rao VM, Zannou EA, et al. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev. 1999;36:3–16.
   PubMed Web of Science ®Google Scholar
• Penalva R, Gonzalez-Navarro CJ, Gamazo C, et al. Zein nanoparticles for oral delivery of quercetin: pharmacokinetic studies and preventive anti-inflammatory effects in a mouse model of endotoxemia. Nanomedicine: NBM. 2017;13:103–110.
   PubMed Web of Science ®Google Scholar
• Lanna EG, Bittencourt VCE, Moreira AMS, et al. Physicochemical characterization and biological activities of the ethanol extract of Bryophyllum pinnatum (Lam.) Oken incorporated in beta-cyclodextrin. J Incl Phenom Macrocycl Chem. 2016;85:247–259.
   Web of Science ®Google Scholar
• McIntyre M, Caffe SE, Michalak RA, et al. Losartan, an orally active angiotensin (AT(1)) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997;74:181–194.
   PubMed Web of Science ®Google Scholar
• Ge LQ, Zhang GG, You BY, et al. The role of losartan in preventing vascular remodeling in spontaneously hypertensive rats by inhibition of the H2O2/VPO1/HOCl/MMPs pathway. Biochem Biophys Res Co. 2017;493:855–861.
   PubMed Web of Science ®Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic-edema associated with angiotensin-converting enzyme-inhibitor therapy – a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234–242.
   PubMed Web of Science ®Google Scholar
• Pitt B, Chang P, Timmermans P. Angiotensin-II receptor antagonists in heart-failure – rationale and design of the evaluation of losartan in the elderly (Elite) trial. Cardiovasc Drug Ther. 1995;9:693–700.
   PubMed Web of Science ®Google Scholar
• de Paula WX, Denadai AM, Santoro MM, et al. Supramolecular interactions between losartan and hydroxypropyl-beta-CD: ESI mass-spectrometry, NMR techniques, phase solubility, isothermal titration calorimetry and anti-hypertensive studies. Int J Pharm. 2011;404:116–123.
   PubMed Web of Science ®Google Scholar
• Jensen CE, dos Santos RA, Denadai AM, et al. Pharmaceutical composition of valsartan: beta-cyclodextrin: physico-chemical characterization and anti-hypertensive evaluation. Molecules. 2010;15:4067–4084.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors K. Phase-solubility techniques. Adv Anal Chem Instr. 1969;4:117–212.
   Google Scholar
• Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin-II receptor blocking-agent, losartan, and its metabolite in human plasma and urine by high-performance liquid-chromatography. J Chromatogr-Biomed Appl. 1992;573:295–301.
   PubMed Web of Science ®Google Scholar
• Neves LAA, Almeida AP, Khosla MC, et al. Metabolism of angiotensin-I in isolated rat hearts – effect of angiotensin-converting enzyme-inhibitors. Biochem Pharmacol. 1995;50:1451–1459.
   PubMed Web of Science ®Google Scholar
• Braga ANG, Lemos MD, Da Silva JR, et al. Effects of angiotensins on day-night fluctuations and stress-induced changes in blood pressure. Am J Physiol-Regul Integr Comp Physiol. 2002;282:R1663–R1671.
   PubMed Web of Science ®Google Scholar
• Turnbull WB, Daranas AH. On the value of c: can low affinity systems be studied by isothermal titration calorimetry? J Am Chem Soc. 2003;125:14859–14866.
   PubMed Web of Science ®Google Scholar
• deSousa FB, Denadai ÂML, Lula ISe, et al. Supramolecular self-assembly of cyclodextrin and higher water soluble guest: thermodynamics and topological studies. J Am Chem Soc. 2008;130:8426–8436.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017–1025.
   PubMed Web of Science ®Google Scholar
• Denadai AML, Santoro MM, Texeira AV, et al. New insights regarding the cyclodextrin/AAS self-assembly: a molar ratio dependent system. Mater Sci Eng C-Mater Biol Appl. 2010;30:417–422.
   Web of Science ®Google Scholar
• Rekharsky MV, Inoue Y. Complexation thermodynamics of cyclodextrins. Chem Rev. 1998;98:1875–1917.
   PubMed Web of Science ®Google Scholar
• Levy GC. C-13 spin-lattice relaxation studies and their application to organic chemical problems. Acc Chem Res. 1973;6:161–169.
   Web of Science ®Google Scholar
• Schneider HJ, Hacket F, Rudiger V, et al. NMR studies of cyclodextrins and cyclodextrin complexes. Chem Rev. 1998;98:1755–1785.
   PubMed Web of Science ®Google Scholar
• Folch-Cano C, Guerrero J, Speisky H, et al. NMR and molecular fluorescence spectroscopic study of the structure and thermodynamic parameters of EGCG/beta-cyclodextrin inclusion complexes with potential antioxidant activity. J Incl Phenom Macrocycl Chem. 2014;78:287–298.
   Web of Science ®Google Scholar
• Kamada M, Hirayama F, Udo K, et al. Cyclodextrin conjugate-based controlled release system: repeated- and prolonged-releases of ketoprofen after oral administration in rats. J Control Release. 2002;82:407–416.
   PubMed Web of Science ®Google Scholar
• Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045–2076.
   PubMed Web of Science ®Google Scholar
• Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins.2. In vivo drug delivery. J Pharm Sci. 1996;85:1142–1169.
   PubMed Web of Science ®Google Scholar